Streamlining End-to-End Amorphous Formulation Development into a Tablet Suitable for Continuous Direct Compression

27 September 2022 10:20 - 10:50

  • Learn how bioavailability enhancement of Amorphous Solid Dispersions (ASDs) can vary from one to three orders of magnitude by optimizing both ASD and tablet formulations and processes
  • Learn how state-of-the-art tools and methodologies can shorten time to Phase I/IND by accelerating formulation and development process  
  • Learn how Dispersome(R) technology, based on natural proteins derived from milk, broaden the formulation landscape enabling high drug load and high performing formulations
  • Learn how ASD formulations manufactured by spray drying can be designed to be directly compressible by Continuous Tableting
  • Learn more how Continuous Tableting is enabling disruptive innovations in the Pharma industry with respect to quality, scalability and improving supply chain flexibility and broadening Lifecycle Management options.

Pedro Valente, R&D Director - Oral Drug Product Development , Hovione